Table 2.
Phase 2 studies of newer radiosensitizers alone or combined
| Schedule [ref] | # pat | Complete R | Survival |
| Gemcitabine 300 mg/m2 (weekly) [95] | -- | 89% | DFS 84%* OS 100% |
| Gemcitabine 300–600 mg/m2 days 1, 8, 15, 40, and 47 [96] | 19 | 80% | NR |
| Gemcitabine 300 mg/m2 (weekly) [97] | 9 | 89% | DFS 77%** OS 100% |
| CDDP 30 mg/m2 + Gemcitabine 20 mg/m2 (both biweekly) [98,99] | 37 | 86% | NR*** |
| CDDP 40 mg/m2 + Gemcitabine 125 mg/m2 (both weekly) [100] | 36 | 89% | DFS 81%° |
| CDDP 40 mg/m2 | 40 | Path 55% | °° |
| Vs | |||
| CDDP 40 mg/m2+ Gemcitabine 125 mg/m2 (both arms weekly) [102] | 43 | Path 77.5% | |
| CDDP 40 mg/m2 + Gemcitabine 125 mg/m2 both weekly) [104] | 20 | 90% | DFS 80% OS 100%°°° |
*Median follow-up 20 months. ** Median follow-up 11 months, trial in patients with renal failure. *** After 3 patients, CDDP was administered weekly. °Median follow-up 14 months. °° Randomized study. Patients underwent radical hysterectomy after EBRT. °°°Median follow-up 12 months.